Ernexa Therapeutics (ERNAW) Net Equity Issued and Repurchased (2014 - 2026)

Ernexa Therapeutics (ERNAW) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $10.5 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (changed N/A YoY) and the FY2025 annual result came in at $4.9 million, up 333.51% from the prior year.
• Net Equity Issued and Repurchased advanced to $10.5 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $12.0 million in Q1 2022 to a low of $1.1 million in Q3 2024.
• A 3-year average of $7.8 million and a median of $9.1 million in 2022 frame the typical range for Net Equity Issued and Repurchased.